Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata [Yahoo! Finance]
Q32 Bio Inc. (QTTB)
Company Research
Source: Yahoo! Finance
April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced that the Company has dosed the first patients in both the Part A open-label extension (OLE) and Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with alopecia areata (AA). "Dosing the first patients in both the Part A OLE and Part B of our SIGNAL-AA trial highlights our ongoing momentum in the clinical development of bempikibart as a potential treatment for AA," said Jodie Morrison , Chief Executive Officer of Q32 Bio. "Based upon the encouraging clinical activity observed to date, including patients with continued responses in long-term follow-up months after completing treatment, robust pharmacologic data and a well-tolerated safety profile, we believe bempikibart has the potential to transform th
Show less
Read more
Impact Snapshot
Event Time:
QTTB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QTTB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QTTB alerts
High impacting Q32 Bio Inc. news events
Weekly update
A roundup of the hottest topics
QTTB
News
- Q32 Bio GAAP EPS of -$0.60 beats by $0.59 [Seeking Alpha]Seeking Alpha
- Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatePR Newswire
- Q32 Bio (NASDAQ:QTTB) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=QTTB&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> frMarketBeat
- Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia AreataPR Newswire
- Q32 Bio (NASDAQ:QTTB) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=QTTB&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> frMarketBeat
QTTB
Earnings
- 3/11/25 - Beat
QTTB
Sec Filings
- 12/4/25 - Form 4
- 12/4/25 - Form 4
- 12/2/25 - Form 144
- QTTB's page on the SEC website